Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RPH-035
- Development stage
- Phase 1
- Lead developer
- R-Pharm
- Modality
- Small Molecules
01
Overview
RPH-035 is an experimental small molecule drug candidate being developed by R-Pharm for the treatment of inflammatory diseases. Currently in the preclinical stage, the program is part of R-Pharm's internal research and development efforts to expand its portfolio in immunology and rheumatology. While the specific molecular target of RPH-035 remains proprietary and has not been detailed in public pipeline disclosures, it is positioned as a novel therapeutic option for managing chronic or acute inflammation. The drug's development is supported by R-Pharm's R&D infrastructure, which includes its subsidiary Ribotech.
Beyond the preview
Go deeper on RPH-035.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RPH-035.